NEW STRATEGY TO TREAT AND PREVENT DISEASES CAUSED BY ENTEROBACTERIAE
The present invention relates to the treatment of diseases induced by Enterobacteriae. The inventors evaluated, in a multicellular in vitro model associating cells representing human enterocytes (Caco-2 cells), goblet mucus secreting cells (HT29-MTX) and M cells, whether Bacteroides fragilis , a non-enterotoxigenic strain, could be useful to limit the severity of the Salmonella Heidelberg infection, with an hypermutator phenotype, by analyzing their impact on growth and mucosal translocation. Thus, the present invention relates to a Bacteroides fragilis strain for use in the treatment of diseases induced by Enterobacteriae in a subject in need thereof.
1 . A method of treating a diseases caused by Enterobacteriae in a subject in need thereof comprising,
administering to the subject a therapeutically effective amount of a Bacteroides fragilis strain.
2 . The method according to claim 1 wherein the Enterobacteriae is a Salmonella selected from the group consisting of Salmonella Heidelberg, Escherichia coli, Yersinia pestis, Klebsiella and Shigella.
3 . The method according to claim 2 wherein the Enterobacteriae is a Salmonella or Escherichia coli.
4 . The method according to claim 1 , wherein the Bacteroides fragilis strain is administered as a probiotic.
5 . The method according to claim 1 , wherein the disease caused by Enterobacteriae is Salmonellosis, typhoid fever, diarrhea Crohn's disease, travelers' diarrhea or ulcerative colitis.
6 . The method according claim 1 , wherein the subject is an animal.
7 . The method according to claim 6 wherein the animal is a fish.
8 . A method of treating an Inflammatory Bowel Disease and/or an Irritable Bowel Syndrome in a subject in need thereof comprising,
administering to the subject a therapeutically effective amount of a Bacteroides fragilis strain.
9 . The method according to claim 8 , wherein the Inflammatory Bowel Disease is Crohn's disease or ulcerative colitis.
10 . The method according to claim 1 , wherein the Bacteroides fragilis strain is a non-toxigenic strain.
11 . A therapeutic composition comprising a Bacteroides fragilis strain.
12 - 13 . (canceled)